Niki BioSolutions, Inc. (NIKI) - Total Liabilities
Based on the latest financial reports, Niki BioSolutions, Inc. (NIKI) has total liabilities worth $4.90 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. For the complete balance sheet picture, see Niki BioSolutions, Inc. asset portfolio.
Niki BioSolutions, Inc. - Total Liabilities Trend (2017–2025)
This chart illustrates how Niki BioSolutions, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore Niki BioSolutions, Inc. long-term investment intensity to see how much of total assets are deployed in long-term investments.
Niki BioSolutions, Inc. Competitors by Total Liabilities
The table below lists competitors of Niki BioSolutions, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cooper Metals Ltd
AU:CPM
|
Australia | AU$58.06K |
|
Samfine Creation Holdings Group Limited
NASDAQ:SFHG
|
USA | $120.51 Million |
|
Bumi Citra Permai Tbk
JK:BCIP
|
Indonesia | Rp383.81 Billion |
|
CodeLab Capital A/S
OL:CODE
|
Norway | Nkr29.46 Million |
|
London Security Plc
LSE:LSC
|
UK | GBX53.59 Million |
|
Tedea Technological Development and Automation Ltd
TA:TEDE
|
Israel | ILA4.79 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Niki BioSolutions, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. Check Niki BioSolutions, Inc. asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Niki BioSolutions, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Niki BioSolutions, Inc. (2017–2025)
The table below shows the annual total liabilities of Niki BioSolutions, Inc. from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.90 Million | +12.56% |
| 2024-12-31 | $4.35 Million | -17.19% |
| 2023-12-31 | $5.26 Million | -59.67% |
| 2022-12-31 | $13.03 Million | +196.15% |
| 2021-12-31 | $4.40 Million | -27.60% |
| 2020-12-31 | $6.08 Million | -33.22% |
| 2019-12-31 | $9.10 Million | -26.17% |
| 2018-12-31 | $12.33 Million | +826.46% |
| 2017-12-31 | $1.33 Million | -- |
About Niki BioSolutions, Inc.
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a r… Read more